MRSN · As filed with the SEC

Mersana Therapeutics balance sheet, by fiscal year

The statement as Mersana Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Consolidated Balance Sheets · USD thousands

USD thousands	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017
Assets
Current assets:
Cash and cash equivalents	107,750	174,561	128,885	177,947	255,094	62,351	59,634	26,591
Short-term marketable securities	—	—	—	—	—	—	—	88,143,000
Short-term marketable securities	—	—	—	—	0	37,439	10,497	—
Short-term marketable securities	26,870	34,523	151,827	—	—	—	—	—
Accounts receivable	—	0	30,000	—	—	—	459	784
Prepaid expenses and other current assets	2,284	4,973	8,507	10,951	3,486	1,536	3,715	2,025
Total current assets	136,904	214,057	319,219	188,898	258,580	101,326	74,305	117,543
Property and equipment, net	—	—	3,985	1,968	1,730	2,164	2,694	2,319
Long-term marketable securities	—	—	—	—	—	—	—	10,482,000
Property and equipment, net	2,203	3,831	—	—	—	—	—	—
Operating lease right-of-use assets	4,578	7,694	10,475	12,889	10,936	2,598	—	—
Other assets, noncurrent	978	478	661	2,356	2,153	1,453	1,503	371
Total assets	144,663	226,060	334,340	206,111	273,399	107,541	78,502	130,715
Liabilities and stockholders’ (deficit) equity
Current liabilities:
Accounts payable	4,330	7,319	13,951	12,321	8,340	7,296	10,727	3,070
Accrued expenses	18,964	21,898	43,184	28,716	16,146	8,986	12,375	6,944
Deferred rent	—	—	—	—	—	—	127,000	232,000
Deferred revenue	—	—	—	—	—	—	—	21,635,000
Deferred revenue	22,168	28,147	30,610	3,944	3,987	4,815	46,196	—
Operating lease liabilities	3,856	3,252	2,798	2,303	1,437	2,219	—	—
Short-term debt	—	2,083	—	—	—	—	—	—
Short-term debt	12,500	—	—	—	0	667	—	—
Other current liabilities	640	938	990	239	93	87	—	—
Total current liabilities	62,458	63,637	91,533	47,523	30,003	24,070	69,425	31,881
Deferred rent, net of current portion	—	—	—	—	—	—	282,000	67,000
Deferred revenue, net of current portion	—	—	—	—	—	—	—	28,773,000
Operating lease liabilities, noncurrent	1,292	5,149	8,575	11,247	10,158	677	—	—
Long-term debt, net	10,950	23,148	24,929	24,626	4,977	4,201	—	—
Deferred revenue, noncurrent	79,464	97,167	117,043	—	—	—	—	—
Other liabilities, noncurrent	8	55	203	974	174	275	—	—
Total liabilities	154,172	189,156	242,283	84,370	45,312	29,223	69,707	—
Stockholders' (deficit) equity
Preferred stock, $0.0001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively	0	0	0	0	0	—	—	—
Common stock, $0.0001 par value; 350,000,000 shares authorized; 115,649,928 and 120,711,745 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively	12	12	11	7	7	5	3	3
Additional paid-in capital	886,022	863,242	746,889	572,213	508,499	270,662	172,966	168,018
Accumulated other comprehensive income	10	11	(152)	—	0	25	(8)	(149)
Accumulated deficit	(895,553)	(826,361)	(654,691)	(450,479)	(280,419)	(192,374)	(164,166)	(97,878)
Total stockholders’ (deficit) equity	(9,509)	36,904	92,057	121,741	228,087	78,318	8,795	69,994
Total liabilities and stockholders’ (deficit) equity	144,663	226,060	334,340	206,111	273,399	107,541	78,502	130,715
Common stock, shares authorized (in shares)	—	350,000,000	350,000,000	—	—	—	—	—

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.